[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"staphylococcus-aureus-endocarditis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:staphylococcus-aureus-endocarditis":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,81,109,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100565065","phase-4-daptomycin-vs-vancomycin-for-the-treatment-of-methicillin-resistant-s-aureus-bacteremia-100565065",false,"NCT06637332","Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia","DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia","DAPTO-SNAP","The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:\n\nInclusion Criteria:\n\n* Methicillin-resistant S. aureus bacteremia\n\nExclusion Criteria:\n\n* Severe allergy or non-severe rash to vancomycin or daptomycin\n* Suspected or confirmed MRSA pneumonia\n* Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg\u002FL or daptomycin MIC greater than or equal to 1mg\u002FL","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.\n\nThis study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)",[27,28,29,30,31],"Staphylococcus Aureus Septicemia","Staphylococcus Aureus Bacteremia","S. Aureus Bacteremia","S. Aureus Bloodstream Infection","Staphylococcus Aureus Endocarditis",[33,34,35,36,37,38],"S. aureus bacteremia","Methicllin resistant","MRSA","S. aureus bloodstream infection","Daptomycin","Vancomycin","RECRUITING","2026-06-18",{"date":42,"type":43},"2026-06-22","ACTUAL",{"date":45,"type":43},"2024-11-14",{"date":47,"type":21},"2027-11",{"name":49,"class":50},"Todd C. Lee MD MPH FIDSA","OTHER",17,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100430531","phase-2-combination-cefazolin-with-ertapenem-for-methicillin-susceptible-staphylococcus-aureus-bacteremia-100430531","NCT04886284","Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia","Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)","CERT","The participant must fulfil all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria to be eligible for this sub-study:\n\nInclusion Criteria:\n\n1. Adult \\>=18 years old\n2. S. aureus bacteremia within the past 48 hours:\n\n   * with any unknown MRSA status (in centers with \\\u003C15% prevalence of MRSA in their annual blood cultures) or known negative MRSA screening swab within 90 days OR\n   * which has already been shown to be MSSA\n3. Current receipt of cefazolin or where it would be clinically appropriate (according to treating ID specialist) to switch to cefazolin as the backbone therapy (open label, non-study drug).\n\nNOTE: Up to an additional 12-24 hours of open label non-study VANCOMYCIN, LINEZOLID or DAPTOMYCIN may be allowed if there is sepsis and clinical concern for MRSA has not been excluded.\n\nExclusion Criteria:\n\nClinical:\n\n1. At time of recruitment, the patient has already clinically improved with at least one subsequent negative culture at \\>24 hours incubation\n2. Anaphylaxis to any beta-lactam antibiotic (and any allergy to ertapenem) Polymicrobial bacteremia (not including skin commensals)\n3. Known seizure disorder\n4. Any receipt of valproic acid\n5. Expected mortality within 48 hours\n6. Need for critical care resources but \"do not resuscitate\" status precludes the receipt of critical care\n7. Unable to provide informed consent and no available healthcare proxy (with ethics approval for deferred consent in cases of severe illness)\n\nAdministrative:\n\n1. Refusal to provide informed consent\n2. Refusal of healthcare team to participate\n3. No reliable means of outpatient contact (telephone\u002Femail\u002Ftext)\n4. Previously enrolled\n5. Patients whose isolate is identified as MRSA post-enrollment will be subsequently excluded (see below).\n\nNote that because MSSA is much more common than MRSA in Canada (90% of all S. aureus bacteremia at MUHC, for example, are MSSA and in the presence of a negative MRSA screening swab or unknown MRSA status, this means that the risk of MRSA is less than 5%). We believe time to combination therapy is likely linked to benefit, therefore we will recruit the patients as soon as S. aureus is identified but potentially prior to confirmation the organism is MSSA. Where possible, rapid MRSA detection techniques will be deployed; however with conventional screening this will mean approximately a 12-24 hours delay. Organisms subsequently identified as MRSA will be excluded from the intention to treat analysis and the sample size will be adjusted accordingly to ensure the total enrollment meets study goals.","100 Years",{"count":62,"type":21},60,[64],"PHASE2","There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed.\n\nThis study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)",[28,27,67,31],"Staphylococcal Sepsis",[69,70,71],"Staphylococcus aureus","Methicillin-susceptible","Bacteremia","2026-05-22",{"date":74,"type":43},"2026-05-27",{"date":76,"type":43},"2024-05-20",{"date":78,"type":21},"2027-07",{"name":49,"class":50},6,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100566078","phase-4-dabigatran-vs-oral-anti-xa-inhibitors-in-s-aureus-bacteremia-100566078","NCT06650501","Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia","DABI-SNAP","The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:\n\nInclusion Criteria:\n\n* Patient is taking (or will imminently start taking) an oral Xa inhibitor (e.g., apixaban, edoxaban, rivaroxaban) for: stroke prevention in atrial fibrillation, treatment or secondary prevention of deep venous thrombosis or pulmonary embolism, prevention of VTE in patients who have undergone elective total hip or total knee replacement surgery provided there are 30 or more days of planned treatment remaining at the time of enrolment.\n\nExclusion Criteria:\n\n* Active bleeding as determine by the site investigator after discussion with the treating team (patient may remain eligible for up to 120 hours from platform entry if condition is resolved and antithrombotic therapy is resumed)\n* Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days\n* Known pregnancy (with testing available for women with childbearing potential)\n* Known use of dabigatran within last month\n* Allergy to dabigatran\n* Concomitant use of amiodarone, ketoconazole, rifampin, verapamil, clopidogrel, prasugrel, or ticagrelor\n* eGFR \\\u003C 30mL\u002Fminute calculated by Cockcroft-Gault equation using adjusted weight \\[patient may remain eligible for up to 120 hours from platform entry if acute kidney injury is resolved such that antithrombotic therapy can be safely resumed\u002Fprescribed\\]\n* Off label use (e.g., metallic mechanical heart valve, left ventricular thrombus, antiphospholipid antibody syndrome)",{"count":20,"type":21},[24],"This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke prevention in atrial fibrillation, prevention or treatment of venous thromboembolism). We will randomize patients to continue their existing medication or change to another medication (dabigatran) which is approved for the original indication.\n\nDabigatran is approved in many countries for the treatment or prevention of venous thromboembolism or preventing stroke in atrial fibrillation. Unlike the other medications listed above, dabigatran seems to have activity against S. aureus in the test tube, in animal models, and in a smaller randomized controlled trial. We wish to determine if changing to dabigatran will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.\n\nThis study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).\n\nIf positive, this study will support a second RCT in people who do not currently have an indication for anticoagulation.",[31,27,28,92,29,30],"Staphylococcus Aureus Bloodstream Infection",[33,36,94,95,96,97,98],"S. aureus endocarditis","Dabigatran","Edoxaban","Rivaroxaban","Apixaban","2026-03-17",{"date":101,"type":43},"2026-03-20",{"date":103,"type":43},"2026-01-15",{"date":105,"type":21},"2030-01",{"name":107,"class":50},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":127,"locationsCount":108},"100566077","phase-4-clopidogrel-vs-aspirin-for-cardiovascular-risk-reduction-in-patients-with-s-aureus-bacteremia-100566077","NCT06650488","Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia","Clopido-SNAP 2","The participant must meet all inclusion and exclusion criteria for the SNAP\n\nPlatform (NCT05137119) and also the following inclusion and exclusion criteria:\n\nInclusion Criteria:\n\n* Patient is taking aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)\n\nExclusion Criteria:\n\n* Active bleeding (allowing up to 3 days from platform entry to randomize in the event anti-thrombotic therapy is resumed)\n* Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days\n* Pregnancy\n* Known receipt of clopidogrel, prasugrel, or ticagrelor within the last month\n* Allergy to clopidogrel\n* Concomitant receipt of oral Xa inhibitor",{"count":20,"type":21},[24],"This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention.\n\nUnlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.\n\nThis study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).\n\nIf positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.",[31,27,92],[121,36,94,122,123],"S. aureus bactremia","aspirin","clopidogrel",{"date":101,"type":43},{"date":103,"type":43},{"date":105,"type":21},{"name":49,"class":50},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":108},"100612446","phase-3-adjunctive-rifampin-for-the-treatment-of-prosthetic-valve-endocarditis-due-to-s-aureus-100612446","NCT07253688","Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus","Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus (RIFA-SNAP)","RIFA-SNAP","Inclusion Criteria:\n\n1. Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and\u002For aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable);\n2. Patient or healthcare proxy provide informed consent.\n\nExclusion Criteria:\n\n1. Death deemed imminent and inevitable within days or patient will be receiving palliative care and has prognosis \\\u003C 90 days according to the treating team;\n2. Patient requires intensive care but has a do not resuscitate order precluding transfer;\n3. Polymicrobial bacteremia (not including skin commensals or other recognized contaminant);\n4. Organism tests as rifampin resistant;\n5. History of hypersensitivity\u002Fanaphylaxis or severe adverse reaction to rifampin;\n6. Category X or other important drug-drug interaction with rifampin which cannot be safely mitigated \\[with as-needed consultation from experts from pharmacy and\u002For internal medicine\u002Fgeriatrics for potential deprescribing\\];\n7. Child Pugh Class C cirrhosis;\n8. Clinician deems rifampin to be mandatory;\n9. Patient has already received \\>3 days of rifampin at time of screening or \\>10 days of total therapy\n10. Pregnancy or breast feeding\n\nAdministrative exclusions:\n\n1. No reliable means of outpatient contact (telephone\u002Femail\u002Ftext);\n2. Previously enrolled;\n3. Prior S. aureus bacteremia within the preceding 180 days",{"count":137,"type":21},330,[139],"PHASE3","This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.",[31,142],"Prosthetic Valve Endocarditis",[33,144,145],"Prosthetic valve endocarditis","Rifampin","2025-12-04",{"date":148,"type":43},"2025-12-10",{"date":150,"type":43},"2025-11-10",{"date":152,"type":21},"2030-07",{"name":49,"class":50}]